+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Peroxisome Proliferator Activated Receptor Delta (NUCI or Nuclear Hormone Receptor 1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator Activated Receptor Beta or NR1C2 or PPARD) - Pipeline Review, H1 2019

  • ID: 4760060
  • Drug Pipelines
  • 96 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 4

FEATURED COMPANIES

  • CymaBay Therapeutics Inc
  • Genfit SA
  • Inception Sciences Inc
  • Inventiva
  • Mitobridge Inc
  • Nippon Chemiphar Co Ltd
  • MORE
Peroxisome Proliferator Activated Receptor Delta (NUCI or Nuclear Hormone Receptor 1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator Activated Receptor Beta or NR1C2 or PPARD) - Pipeline Review, H1 2019

Summary

Peroxisome Proliferator Activated Receptor Delta (NUCI or Nuclear Hormone Receptor 1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator Activated Receptor Beta or NR1C2 or PPARD) - Peroxisome proliferator-activated receptor delta is a nuclear receptor that in humans is encoded by the PPARD gene. PPAR-delta is a nuclear hormone receptor that governs a variety of biological processes and involved in the development of several chronic diseases, including diabetes, obesity, atherosclerosis, and cancer. The expression of this gene is found to be elevated in colorectal cancer cells. The elevated expression can be repressed by adenomatosis polyposis coli (APC), a tumor suppressor protein involved in the APC/beta-catenin signaling pathway.

Peroxisome Proliferator Activated Receptor Delta (NUCI or Nuclear Hormone Receptor 1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator Activated Receptor Beta or NR1C2 or PPARD) pipeline Target constitutes close to 16 molecules. Out of which approximately 13 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are 4, 4, 2 and 3 respectively.

Similarly, the universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively. Report covers products from therapy areas Metabolic Disorders, Gastrointestinal, Central Nervous System, Oncology, Genetic Disorders, Genito Urinary System And Sex Hormones, Musculoskeletal Disorders, Ophthalmology, Immunology and Respiratory which include indications Non-Alcoholic Steatohepatitis (NASH), Acute Renal Failure (ARF) (Acute Kidney Injury), Duchenne Muscular Dystrophy, Dyslipidemia, Mitochondrial Diseases, Non Alcoholic Fatty Liver Disease (NAFLD), Primary Biliary Cirrhosis, Type 2 Diabetes, Alzheimer's Disease, Bone Disorders, Bone Fracture, Colitis, Familial Chylomicronemia (Type I Hyperlipoproteinemia), Hepatocellular Carcinoma, Huntington Disease, Idiopathic Pulmonary Fibrosis, Inflammation, Keratoconjunctivitis Sicca (Dry Eye), Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy), Liver Diseases, Liver Fibrosis, MELAS Syndrome (Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-Like Episodes), Metabolic Syndrome, Obesity, Osteoarthritis, Osteoporosis and Parkinson's Disease.

The latest report Peroxisome Proliferator Activated Receptor Delta - Pipeline Review, H1 2019, outlays comprehensive information on the Peroxisome Proliferator Activated Receptor Delta (NUCI or Nuclear Hormone Receptor 1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator Activated Receptor Beta or NR1C2 or PPARD) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Peroxisome Proliferator Activated Receptor Delta (NUCI or Nuclear Hormone Receptor 1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator Activated Receptor Beta or NR1C2 or PPARD) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The report provides a snapshot of the global therapeutic landscape for Peroxisome Proliferator Activated Receptor Delta (NUCI or Nuclear Hormone Receptor 1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator Activated Receptor Beta or NR1C2 or PPARD)
  • The report reviews Peroxisome Proliferator Activated Receptor Delta (NUCI or Nuclear Hormone Receptor 1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator Activated Receptor Beta or NR1C2 or PPARD) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Peroxisome Proliferator Activated Receptor Delta (NUCI or Nuclear Hormone Receptor 1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator Activated Receptor Beta or NR1C2 or PPARD) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Peroxisome Proliferator Activated Receptor Delta (NUCI or Nuclear Hormone Receptor 1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator Activated Receptor Beta or NR1C2 or PPARD) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Peroxisome Proliferator Activated Receptor Delta (NUCI or Nuclear Hormone Receptor 1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator Activated Receptor Beta or NR1C2 or PPARD) targeted therapeutics
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Peroxisome Proliferator Activated Receptor Delta (NUCI or Nuclear Hormone Receptor 1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator Activated Receptor Beta or NR1C2 or PPARD)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Peroxisome Proliferator Activated Receptor Delta (NUCI or Nuclear Hormone Receptor 1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator Activated Receptor Beta or NR1C2 or PPARD) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • CymaBay Therapeutics Inc
  • Genfit SA
  • Inception Sciences Inc
  • Inventiva
  • Mitobridge Inc
  • Nippon Chemiphar Co Ltd
  • MORE
Introduction

Report Coverage

Peroxisome Proliferator Activated Receptor Delta (NUCI or Nuclear Hormone Receptor 1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator Activated Receptor Beta or NR1C2 or PPARD) - Overview

Peroxisome Proliferator Activated Receptor Delta (NUCI or Nuclear Hormone Receptor 1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator Activated Receptor Beta or NR1C2 or PPARD) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Peroxisome Proliferator Activated Receptor Delta (NUCI or Nuclear Hormone Receptor 1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator Activated Receptor Beta or NR1C2 or PPARD) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Peroxisome Proliferator Activated Receptor Delta (NUCI or Nuclear Hormone Receptor 1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator Activated Receptor Beta or NR1C2 or PPARD) - Companies Involved in Therapeutics Development

Chipscreen Biosciences Ltd

CymaBay Therapeutics Inc

Genfit SA

Inception Sciences Inc

Inventiva

Mitobridge Inc

Nippon Chemiphar Co Ltd

Senju Pharmaceutical Co Ltd

T3D Therapeutics Inc

Peroxisome Proliferator Activated Receptor Delta (NUCI or Nuclear Hormone Receptor 1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator Activated Receptor Beta or NR1C2 or PPARD) - Drug Profiles

CS-038 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drugs to Modulate PPAR-Delta for Metabolic and Musculoskeletal Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

elafibranor - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

fonadelpar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HPP-593 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

lanifibranor - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MA-0204 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MA-0211 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MA-0217 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NC-2400 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

seladelpar lysine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Agonize PPAR Delta for Mitochondrial Diseases - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize PPARA and PPARD for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Agonize PPAR-delta for Non-Alcoholic Steatoheptatis and Obesity - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit PPAR Beta and PPAR Delta for Metabolic Disorders, Inflammatory Diseases and Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

T-3D959 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Peroxisome Proliferator Activated Receptor Delta (NUCI or Nuclear Hormone Receptor 1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator Activated Receptor Beta or NR1C2 or PPARD) - Dormant Products

Peroxisome Proliferator Activated Receptor Delta (NUCI or Nuclear Hormone Receptor 1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator Activated Receptor Beta or NR1C2 or PPARD) - Discontinued Products

Peroxisome Proliferator Activated Receptor Delta (NUCI or Nuclear Hormone Receptor 1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator Activated Receptor Beta or NR1C2 or PPARD) - Product Development Milestones

Featured News & Press Releases

Mar 12, 2019: Genfit to study elafibranor in Phase II trial for paediatric NASH

Feb 21, 2019: Inventiva announces further progress achieved in the clinical development of lanifibranor for the treatment of NASH

Feb 19, 2019: CymaBay Therapeutics announces early enrollment of a phase 2b study of seladelpar in patients with nonalcoholic steatohepatitis

Feb 19, 2019: Inventiva’s lanifibranor fails to meet endpoint in FASST trial

Feb 15, 2019: CymaBay Therapeutics announces seladelpar granted breakthrough therapy designation by the FDA for the treatment of primary biliary cholangitis

Feb 04, 2019: INVENTIVA : New results on lanifibranor to be presented at the International Liver Congress 2019

Dec 17, 2018: GENFIT: Positive 30-month DSMB recommendation for continuation of phase 3 RESOLVE-IT study of Elafibranor in NASH

Dec 06, 2018: GENFIT: Positive phase 2 results from study of Elafibranor in primary biliary cholangitis

Nov 13, 2018: Cymabay Therapeutics presents positive results from its ongoing phase 2 study of Seladelpar in patients with PBC at The Liver Meeting 2018

Oct 30, 2018: Cymabay announces the initiation of the Seladelpar global phase 3 registration study (enhance) for the treatment of primary biliary cholangitis and additional corporate updates

Oct 15, 2018: Inventiva announces last visit by last patient in its phase IIb SSC trial and second positive DSMB review in its phase IIbnash trial with Lanifibranor

Oct 10, 2018: Inventiva Announces Two Poster Presentations at the American College of Rheumatology Conference

Oct 03, 2018: Cymabay Therapeutics announces additional positive results from its ongoing phase 2 study of Seladelpar in patients with PBC will be presented during the late-breaking session at the liver meeting

Oct 02, 2018: GENFIT: New data to be presented at 2018 AASLD meeting, ahead of key results expected in 2018 and 2019

Aug 31, 2018: GENFIT announces its upcoming participation in a number of investor and NASH-specific events over the next two months

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact the Publisher

Disclaimer

List of Tables

Number of Products under Development by Stage of Development, H1 2019

Number of Products under Development by Therapy Areas, H1 2019

Number of Products under Development by Indications, H1 2019

Number of Products under Development by Companies, H1 2019

Products under Development by Companies, H1 2019

Number of Products under Investigation by Universities/Institutes, H1 2019

Products under Investigation by Universities/Institutes, H1 2019

Number of Products by Stage and Mechanism of Actions, H1 2019

Number of Products by Stage and Route of Administration, H1 2019

Number of Products by Stage and Molecule Type, H1 2019

Pipeline by Chipscreen Biosciences Ltd, H1 2019

Pipeline by CymaBay Therapeutics Inc, H1 2019

Pipeline by Genfit SA, H1 2019

Pipeline by Inception Sciences Inc, H1 2019

Pipeline by Inventiva, H1 2019

Pipeline by Mitobridge Inc, H1 2019

Pipeline by Nippon Chemiphar Co Ltd, H1 2019

Pipeline by Senju Pharmaceutical Co Ltd, H1 2019

Pipeline by T3D Therapeutics Inc, H1 2019

Dormant Products, H1 2019

Discontinued Products, H1 2019

List of Figures

Number of Products under Development by Stage of Development, H1 2019

Number of Products under Development by Therapy Areas, H1 2019

Number of Products under Development by Top 10 Indications, H1 2019

Number of Products by Mechanism of Actions, H1 2019

Number of Products by Stage and Mechanism of Actions, H1 2019

Number of Products by Routes of Administration, H1 2019

Number of Products by Stage and Routes of Administration, H1 2019

Number of Products by Stage and Molecule Type, H1
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Chipscreen Biosciences Ltd
  • CymaBay Therapeutics Inc
  • Genfit SA
  • Inception Sciences Inc
  • Inventiva
  • Mitobridge Inc
  • Nippon Chemiphar Co Ltd
  • Senju Pharmaceutical Co Ltd
  • T3D Therapeutics Inc
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Order Online - visit: https://www.researchandmarkets.com/reports/4760060
Adroll
adroll